Illumina Inc

2026-02-21 18:14:25

Rami Mehio, Head of Software and Informatics at Illumina, discusses Illumina's crucial role in the UK Biobank's whole genome sequencing project, highlighting their contributions in sequencing technology and bioinformatics using DRAGEN and ICA cloud platform. He elaborates on the challenges of analyzing 500,000 genomes, such as computational infrastructure and data aggregation, and how Illumina's technology improved variant identification and data compatibility. The interview also touches on the broader implications of these advancements for precision medicine, drug discovery, and the importance of collaboration in genomic research.

2026-02-21 15:03:43

The global genomics market is projected to grow significantly from USD 33.90 billion in 2023 to USD 157.47 billion by 2033, driven by increasing demand for novel therapeutic and research applications, technological advancements, and supportive government funding. Key drivers include personalized medicine, falling sequencing costs, and growing applications in understanding and treating genetic disorders and diseases like cancer. Challenges persist in managing and securely storing the vast amounts of generated genomic data.

2026-02-21 01:50:21

Illumina (NASDAQ:ILMN) shareholders have experienced significant losses, with the stock plunging 78% over the last three years and 42% in the past year. The recent 6.8% drop adds to the concern, raising questions about the company's long-term stock performance despite maintaining top-line revenue and paying dividends. While the company has been profitable in the past, its current trailing twelve-month loss suggests an inconsistent profit record.

2026-02-20 09:40:13

Patricia Leckman, SVP and Chief People Officer at Illumina, sold 2,370 shares of common stock for $275,346 on February 18, 2026, and an additional 1,304 shares for $151,929 on February 15, 2026. Despite these insider sales, InvestingPro data indicates aggressive share buybacks by management and the company recently surpassed Q4 2025 earnings and revenue expectations. Illumina's stock has seen an 80.18% price return over the past six months and holds a "fair" financial health score.

2026-02-18 19:27:41

Illumina stock is down 80% from its all-time highs, but recent Q4 2025 earnings show promise with revenue beat and clinical consumables growth. The company completed the SomaLogic acquisition, adding proteomics, which is expected to contribute to revenue growth despite some EPS dilution and margin compression. A TIKR valuation model projects an 11% annualized return to $158 by December 2028, contingent on sustained clinical consumables momentum and successful integration of SomaLogic.

2026-02-17 19:57:23

Illumina, Inc. announced that its management team will participate in the TD Cowen 46th Annual Health Care Conference on March 3, 2026. A fireside chat is scheduled for 12:10 p.m. PT (3:10 p.m. ET) and a webcast will be available on Illumina's investor relations website, with a replay archived for at least 30 days. Illumina is a global leader in DNA sequencing and array-based technologies, focusing on improving human health through genomics.